Scancell (LON:SCLP) Releases Earnings Results

Key Points

• Scancell reported GBX 1.26 earnings per share for the latest quarter, reflecting the firm's ongoing development in cancer treatments.
• The company's stock, which opened at GBX 8.45, has seen significant fluctuations, with a fifty-two week range from GBX 7.26 to GBX 18.
• Insider Martin Diggle recently purchased 102,236 shares at GBX 11 each, indicating a continued confidence from company insiders, who own 15.15% of the stock.

Scancell (LON:SCLP - ) issued its quarterly earnings data on Thursday. The company reported GBX (1.26) earnings per share for the quarter, Digital Look Earnings reports.

Scancell Price Performance

Shares of LON SCLP opened at GBX 8.45 on Thursday. Scancell has a fifty-two week low of GBX 7.26 and a fifty-two week high of GBX 18. The firm's 50-day simple moving average is GBX 10.11 and its 200 day simple moving average is GBX 9.62. The company has a quick ratio of 13.01, a current ratio of 3.42 and a debt-to-equity ratio of -566.79. The stock has a market cap of £87.64 million, a P/E ratio of -406.01 and a beta of 0.35.

Insider Buying and Selling at Scancell

In other news, insider Martin Diggle bought 102,236 shares of the stock in a transaction that occurred on Thursday, August 7th. The shares were purchased at an average cost of GBX 11 per share, with a total value of £11,245.96. 15.15% of the stock is currently owned by corporate insiders.

Scancell Company Profile

Scancell LSE: SCLP is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. Scancell has developed a pipeline of ‘off-the-shelf' vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.